Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

221 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Outcomes with chimeric antigen receptor t-cell therapy in relapsed or refractory acute myeloid leukemia: a systematic review and meta-analysis.
Shahzad M, Nguyen A, Hussain A, Ammad-Ud-Din M, Faisal MS, Tariq E, Ali F, Butt A, Anwar I, Chaudhary SG, Lutfi F, Ahmed N, Singh AK, Hematti P, McGuirk JP, Mushtaq MU. Shahzad M, et al. Among authors: hematti p. Front Immunol. 2023 Apr 24;14:1152457. doi: 10.3389/fimmu.2023.1152457. eCollection 2023. Front Immunol. 2023. PMID: 37168849 Free PMC article. Review.
Use of endpoints in phase III randomized controlled trials for acute myeloid leukemia over the last 15 years: a systematic review.
Shahzad M, Chaudhary SG, Tariq E, Mushtaq AH, Anwar I, Ahmed N, Bansal R, Lutfi F, Balusu R, Abdelhakim H, Yacoub A, Hematti P, Singh AK, McGuirk JP, Mushtaq MU. Shahzad M, et al. Among authors: hematti p. Leuk Lymphoma. 2023 Feb;64(2):273-282. doi: 10.1080/10428194.2022.2136947. Epub 2022 Oct 25. Leuk Lymphoma. 2023. PMID: 36282773
Outcomes of Tyrosine Kinase Inhibitors Maintenance Therapy with or without Allogeneic Hematopoietic Stem Cell Transplantation in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia in First Complete Remission: A Systematic Review and Meta-Analysis.
Shahzad M, Hussain A, Tariq E, Anwar I, Faisal MS, Syed L, Karam A, Chaudhary SG, Ahmed N, Bansal R, Khurana S, Singh AK, Byrd KP, Hematti P, Abhyankar SH, McGuirk JP, Mushtaq MU. Shahzad M, et al. Among authors: hematti p. Clin Lymphoma Myeloma Leuk. 2023 Mar;23(3):178-187. doi: 10.1016/j.clml.2023.01.002. Epub 2023 Jan 12. Clin Lymphoma Myeloma Leuk. 2023. PMID: 36682989 Review.
Outcomes with allogeneic hematopoietic stem cell transplantation in TP53-mutated myelodysplastic syndrome: A systematic review and meta-analysis.
Shahzad M, Iqbal Q, Tariq E, Ammad-Ud-Din M, Butt A, Mushtaq AH, Ali F, Chaudhary SG, Anwar I, Gonzalez-Lugo JD, Abdelhakim H, Ahmed N, Hematti P, Singh AK, McGuirk JP, Mushtaq MU. Shahzad M, et al. Among authors: hematti p. Crit Rev Oncol Hematol. 2024 Apr;196:104310. doi: 10.1016/j.critrevonc.2024.104310. Epub 2024 Feb 27. Crit Rev Oncol Hematol. 2024. PMID: 38423375 Free article. Review.
Incidence and Impact of Fungal Infections in Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis and Haploidentical Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis.
Papanicolaou GA, Chen M, He N, Martens MJ, Kim S, Batista MV, Bhatt NS, Hematti P, Hill JA, Liu H, Nathan S, Seftel MD, Sharma A, Waller EK, Wingard JR, Young JH, Dandoy CE, Perales MA, Chemaly RF, Riches M, Ustun C. Papanicolaou GA, et al. Among authors: hematti p. Transplant Cell Ther. 2024 Jan;30(1):114.e1-114.e16. doi: 10.1016/j.jtct.2023.09.017. Epub 2023 Sep 28. Transplant Cell Ther. 2024. PMID: 37775070
TCR-α/β and CD19 depleted stem cell grafts from haploidentical donors for allogeneic transplantation in patients with relapsed lymphoma: a single-center experience.
Kenkre VP, Bradley K, Milton A, Burkholder JK, Grindle K, McMannes J, Kim K, Callander N, Juckett M, Longo W, Hematti P. Kenkre VP, et al. Among authors: hematti p. Leuk Lymphoma. 2023 Nov-Dec;64(11):1875-1879. doi: 10.1080/10428194.2023.2240918. Epub 2023 Aug 10. Leuk Lymphoma. 2023. PMID: 37585704 No abstract available.
Critical Illness Risk and Long-Term Outcomes Following Intensive Care in Pediatric Hematopoietic Cell Transplant Recipients.
Zinter MS, Brazauskas R, Strom J, Chen S, Bo-Subait S, Sharma A, Beitinjaneh A, Dimitrova D, Guilcher G, Preussler J, Myers K, Bhatt NS, Ringden O, Hematti P, Hayashi RJ, Patel S, De Oliveira SN, Rotz S, Badawy SM, Nishihori T, Buchbinder D, Hamilton B, Savani B, Schoemans H, Sorror M, Winestone L, Duncan C, Phelan R, Dvorak CC. Zinter MS, et al. Among authors: hematti p. medRxiv [Preprint]. 2023 Aug 5:2023.07.31.23293444. doi: 10.1101/2023.07.31.23293444. medRxiv. 2023. PMID: 37577706 Free PMC article. Updated. Preprint.
221 results